Altimmune (ALT)

• Market cap: $453M
• 1 day: 3.43%
• 5 days: -7.18%
• 1 month: -19.56%
• 3 months: -28.03%
• 6 months: -0.28%
• Year to date: 3.13%
• 1 year: -39.36%
• 5 years: -78.38%
• 10 years: -99.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 57